Loading...
XSHE
000915
Market cap843mUSD
Jul 10, Last price  
24.52CNY
1D
0.45%
1Q
-22.38%
Jan 2017
-24.34%
Name

Shandong WIT Dyne Health Co Ltd

Chart & Performance

D1W1MN
XSHE:000915 chart
P/E
10.74
P/S
2.58
EPS
2.28
Div Yield, %
10.24%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
4.12%
Revenues
2.23b
+4.40%
527,433,133495,673,120538,347,699499,397,489560,278,543716,985,900830,249,9541,095,341,7461,373,956,9061,232,966,3481,544,725,0681,767,233,1941,526,231,2691,799,947,8461,821,033,9572,027,141,9722,341,075,5942,484,165,6982,134,491,1882,228,386,030
Net income
535m
+3.78%
10,355,09812,276,34913,691,71434,414,27870,542,05693,750,571121,590,673153,280,360217,378,365152,456,091198,385,162243,200,952129,690,461204,102,273290,756,643380,262,705526,864,053585,262,091515,594,981535,082,160
CFO
1.27b
+36.78%
51,948,722101,196,84493,802,155129,393,828189,514,198139,091,579163,484,225216,052,537272,411,394290,236,595500,913,721426,108,916538,562,683243,541,497735,551,506755,852,5931,196,404,5391,174,684,951929,608,2331,271,522,660
Dividend
Oct 17, 20250.5 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Wit Dyne Health Co., Ltd., founded on June 26, 1993, and headquartered in Jinan, China, dedicates its operations to the investigation, creation, and manufacture of pharmaceuticals and health solutions tailored for children. The company offers a wide array of products, which include vitamin A and D drops, effervescent granules containing compound calcium carbonate, licorice zinc granules, iron dextran granules, and pediatric ibuprofen suppositories. Its offerings further extend to specialized medications such as azithromycin granules, dimercaptosuccinic acid capsules, rifaximin dry suspension, and oral rehydration salt powder.
IPO date
Jun 09, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT